We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Shares of cannabis-related stocks and ETFs surged lately following a report that some strains of medical marijuana are proving effective to treat coronavirus. The report indicates that the medicinal marijuana could block up to 70% of the proteins used by the virus to infect cells. As a result, the entire cannabis sector jumped late last week.
If this was not enough, Canada’s Aurora Cannabis has agreed to buy U.S.-based CBD company Reliva, in order to enter the U.S. market. According to the Brightfield Group research firm, CBD sales are projected to surge to $24 billion in U.S. retail sales by 2025, as quoted on CNBC.
Cannabis Investing in Vogue Amid Pandemic
Marijuana stocks have performed better than the broader market in the difficult phase of coronavirus pandemic. The pure-play marijuana ETF MJ added 17.7% past month versus 5.3% gains in the S&P 500 index (as of May 22, 2020).
Amid widespread COVID-19-related lockdowns and store closures, many cannabis dispensaries received “essential business” designations, noted Global X. As a result, consumers hoarded medicinal and recreational cannabis in the quarter, which should result in better revenues for the pot companies. Sales have also been pretty strong for marijuana amid the latest virus outbreak.
Sales have been surging in Canada too where the new recreational cannabis market, named Rec 2.0, was launched in late 2019. Aurora Cannabis (ACB - Free Report) recently stated that Rec 2.0 products could account for about 20% of total sales.
New store openings are another positive. In first-quarter 2020, Canada opened 191 new stores taking its total to 806, per the Global X report. The United States has nine times more dispensary licenses than Canada, which should facilitate more store openings in the coming days in the United States.
Investors should also note that sin stocks tend to perform better even in the time of recession. With marijuana apparently being an addictive item, sales are expected to remain almost unruffled in the ongoing recession.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
How Cannabis ETFs Beat S&P 500 Past Month
Shares of cannabis-related stocks and ETFs surged lately following a report that some strains of medical marijuana are proving effective to treat coronavirus. The report indicates that the medicinal marijuana could block up to 70% of the proteins used by the virus to infect cells. As a result, the entire cannabis sector jumped late last week.
If this was not enough, Canada’s Aurora Cannabis has agreed to buy U.S.-based CBD company Reliva, in order to enter the U.S. market. According to the Brightfield Group research firm, CBD sales are projected to surge to $24 billion in U.S. retail sales by 2025, as quoted on CNBC.
Cannabis Investing in Vogue Amid Pandemic
Marijuana stocks have performed better than the broader market in the difficult phase of coronavirus pandemic. The pure-play marijuana ETF MJ added 17.7% past month versus 5.3% gains in the S&P 500 index (as of May 22, 2020).
Overall, Global X Cannabis ETF surged 35.4% past month, The Cannabis ETF added 34.2%, AdvisorShares Pure Cannabis ETF (YOLO - Free Report) gained 34.4%, Amplify Seymour Cannabis ETF (CNBS - Free Report) advanced 26.3% and Cambria Cannabis ETF (TOKE - Free Report) gained about 22.5% (read: Are Marijuana Stocks & ETFs Coronavirus-Proof?).
Amid widespread COVID-19-related lockdowns and store closures, many cannabis dispensaries received “essential business” designations, noted Global X. As a result, consumers hoarded medicinal and recreational cannabis in the quarter, which should result in better revenues for the pot companies. Sales have also been pretty strong for marijuana amid the latest virus outbreak.
Sales have been surging in Canada too where the new recreational cannabis market, named Rec 2.0, was launched in late 2019. Aurora Cannabis (ACB - Free Report) recently stated that Rec 2.0 products could account for about 20% of total sales.
New store openings are another positive. In first-quarter 2020, Canada opened 191 new stores taking its total to 806, per the Global X report. The United States has nine times more dispensary licenses than Canada, which should facilitate more store openings in the coming days in the United States.
Investors should also note that sin stocks tend to perform better even in the time of recession. With marijuana apparently being an addictive item, sales are expected to remain almost unruffled in the ongoing recession.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>